ArticleBioMed research international2014
In silico molecular docking and in vitro antidiabetic studies of dihydropyrimido[4,5-a]acridin-2-amines.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Deciphering the nematicidal potential of plant-origin bioactive compounds against root-knot nematode, Meloidogyne incognita, through toxicity and molecular approaches.Pest management science · 2026Article
- Hepatoprotective Properties ofFood science & nutrition · 2025Article
- Exploring the potential of pheophorbide A, a chlorophyll-derived compound in modulating GLUT for maintaining glucose homeostasis.Frontiers in endocrinology · 2024Article
- Inhibition Kinetics and Theoretical Studies onJournal of xenobiotics · 2023Article
- Bacteriocin-Nanoconjugates (Bac10307-AgNPs) Biosynthesized fromPharmaceutics · 2023Article
- Phytochemical Analysis and Binding Interaction of Cotton Seed Cake Derived Compounds with Target Protein ofLife (Basel, Switzerland) · 2022Article
- Molecular docking analysis and evaluation of the antimicrobial properties of the constituents of Geranium wallichianum D. Don ex Sweet from Kashmir Himalaya.Scientific reports · 2022Article
- GC-MS/MS Quantification of EGFR Inhibitors,Molecules (Basel, Switzerland) · 2022Article
- GC-MS and molecular docking analyses of phytochemicals from the underutilized plant, Parkia timoriana revealed candidate anti-cancerous and anti-inflammatory agents.Scientific reports · 2022Article
- Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives.Frontiers in endocrinology · 2022Article
- In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes.Biomolecules · 2021Review
- In silico analysis of a potential antidiabetic phytochemical erythrin against therapeutic targets of diabetes.In silico pharmacology · 2021Article
- GC-MS analysis of phytoconstituents from Amomum nilgiricum and molecular docking interactions of bioactive serverogenin acetate with target proteins.Scientific reports · 2020Article
- Analysis on evolutionary relationship of amylases from archaea, bacteria and eukaryota.World journal of microbiology & biotechnology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An in vitro antidiabetic activity on α -amylase and α -glucosidase activity of novel 10-chloro-4-(2-chlorophenyl)-12-phenyl-5,6-dihydropyrimido[4,5-a]acridin-2-amines (3a-3f) were evaluated. Structures of the synthesized molecules were studied by FT-IR, (1)H NMR, (13)C NMR, EI-MS, and single crystal X-ray structural analysis data. An in silico molecular docking was performed on synthesized molecules (3a-3f). Overall studies indicate that compound 3e is a promising compound leading to the development of selective inhibition of α -amylase and α -glucosidase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.